Matthaei S, Hamann A
Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendort, Hamburg.
Fortschr Med. 1997 Apr 30;115(12):35-6, 39.
Intensified insulin therapy of type I diabetics can now be rendered more patient-friendly through the use of rapid-action insulin. Thus, for example, the rapid absorption of the monomeric lispro insulin (Humalog) out of the subcutaneous fatty tissue obviates the need to observe a delay between injection and meal, and the changed kinetics of action reduce the danger of postprandial episodes of hypoglycemia. In addition to practice-relevant hints on the use of these new short-acting insulins in intensified insulin therapy, this short article reviews the current state of the development of a new long-acting insulin that is shortly to be tested in an international multi-center phase III study.
通过使用速效胰岛素，I型糖尿病患者的强化胰岛素治疗现在可以变得对患者更加友好。例如，单体赖脯胰岛素（优泌乐）从皮下脂肪组织中的快速吸收消除了注射与进餐之间需要等待的时间，并且作用动力学的改变降低了餐后低血糖发作的风险。除了关于在强化胰岛素治疗中使用这些新型短效胰岛素的与实践相关的提示外，这篇短文还综述了一种新型长效胰岛素的当前研发状态，该胰岛素即将在一项国际多中心III期研究中进行测试。
